Qurient Co. Ltd. | Income Statement

Fiscal year is January-December. All values KRW Thousands.
2013
2014
2015
2016
2017
Sales/Revenue
-
215,280.00
-
-
-
Cost of Goods Sold (COGS) incl. D&A
32,525.00
85,154.00
139,021.00
114,375.00
85,540.00
Gross Income
32,525.00
130,126.00
139,021.00
114,375.00
85,540.00
SG&A Expense
4,303,869.90
6,774,651.20
8,088,216.70
10,940,284.00
12,620,583.40
EBIT
4,336,610.90
6,645,826.20
8,230,446.70
11,076,581.00
12,723,839.50
Unusual Expense
489,928.00
2,262,529.00
-
-
-
Non Operating Income/Expense
4,252.10
10,865.40
57,851.00
21,503.60
22,952.60
Interest Expense
1,013,371.90
1,966,526.90
1,254,588.00
-
-
Pretax Income
4,820,300.90
10,706,197.50
9,301,977.70
10,535,977.50
12,183,048.90
Income Tax
-
-
-
-
13,151.30
Consolidated Net Income
4,820,300.90
10,706,197.50
9,301,977.70
10,535,977.50
12,196,200.10
Net Income
4,820,300.90
10,706,197.50
9,301,977.70
10,535,977.50
12,196,200.10
Net Income After Extraordinaries
4,820,300.90
10,706,197.50
9,301,977.70
10,535,977.50
12,196,200.10
Net Income Available to Common
4,820,300.90
10,706,197.50
9,301,977.70
10,535,977.50
12,196,200.10
EPS (Basic)
681.00
1,512.00
1,313.00
1,508.00
1,637.00
Basic Shares Outstanding
7,083.10
7,083.10
7,083.10
6,987.70
7,448.50
EPS (Diluted)
680.54
1,511.52
1,313.27
1,507.80
1,637.39
Diluted Shares Outstanding
7,083.10
7,083.10
7,083.10
6,987.70
7,448.50
EBITDA
4,304,085.90
6,560,672.20
8,091,425.70
10,962,206.00
12,638,299.50
Other Operating Expense
216.00
1,301.00
3,209.00
21,922.00
17,716.00
Non-Operating Interest Income
35,501.80
179,550.00
125,206.00
519,100.00
517,838.00

About Qurient Co.

View Profile
Address
8/F, Tower C, PDCC Building
Seongnam GY 13487
Korea, Republic Of
Employees -
Website http://www.qurient.com
Updated 09/14/2018
Qurient Co., Ltd. engages in the development of novel therapeutics. Its research and development pipeline includes tuberculosis, atopic dermatitis, asthma and cancer. It offers drug development management and business development services.